Objective To investigate the effect of NSC348884, a nucleophosmin small molecular inhibitor , on the growth of hepatocellular carcinoma cell line HepG2 and its underlying mechanism. Methods After HepG2 cells were treated by NSC348884 for 4 days, the effect of HepG2 cells on proliferation was measured by methyl thiazolyl tetrazolium ( MTT) assay, the expression variation of nucleophosmin oligomer and monomer was measured using Western blotting, and cell apoptotic rate was detected by flow cytometry. Results The proliferation of HepG2 cells was remarkably inhibited by NSC348884 treatment when the drug concentration ranged from 1 μmol/L to 10 punol/L ( P < 0. 05), with a 50% inhibiting concentration of 1.4 ^mol/L After treatment for 24 hours, the expression level of nucleophosmin oligomer decreased obviously while that of nucleophosmin monomer increased ( both P < 0. 05 ). After treatment by 1μmol/L and 2 μmol/L NSC348884, the 24-hour apoptotic rates of HepG2 cells were (13. 770 ± 0. 335) % and (19. 021 ± 0. 237) % , respectively, which were significantly higher than in the control group (6. 950 ± 0. 207 ) % ( P < 0. 05 ). Conclusion NSC348884 can promote the transformation of nucleophosmin oligomer to monomer and thus inhibit the growth of hepatic carcinoma cell line HepG2 in vitro.%目的 探讨核磷蛋白小分子抑制剂NSC348884对肝癌细胞HepG2体外生长的抑制作用及其作用机制.方法 应用核磷蛋白小分子抑制剂NSC348884处理HepG2细胞,噻唑蓝法检测HepG2细胞增殖的变化,蛋白印迹检测核磷蛋白寡聚物和单体表达变化,流式细胞仪检测HepG2细胞凋亡率的变化.结果 HepG2细胞经NSC348884作用4d后,药物浓度在1 ～ 10 μmol/L时明显抑制HepG2细胞的增殖(P＜0.05),半数抑制浓度为1.4μmol/L;药物作用24h后,核磷蛋白寡聚物表达水平明显降低,而单体表达水平明显升高(P＜0.05)；经1 μmol/L、2μmol/L NSC348884处理后,HepG2细胞24h凋亡率分别为(13.770 ±0.335)％、(19.021±0.237)％,高于对照组的(6.950±0.207)％ (P ＜0.05).结论 NSC348884能促进HepG2细胞核磷蛋白寡聚物向单体的转化,从而抑制肝癌HepG2细胞的体外生长.
展开▼
